Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
Rhea-AI Summary
Vericel (NASDAQ:VCEL) announced it will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026. A live webcast of the presentation will be accessible through the Investor Relations section of Vericel's website at http://investors.vcel.com.
Positive
- None.
Negative
- None.
News Market Reaction – VCEL
In the Jun 9 session, VCEL gained 3.52%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | -4.5% | Strong Q1 growth and raised 2026 revenue guidance. |
| Apr 23 | Earnings date set | Neutral | +0.1% | Announcement of Q1 2026 results date and call details. |
| Apr 02 | BARDA contract | Positive | +4.8% | Ten-year BARDA award up to $197M for NexoBrid. |
| Mar 04 | FDA facility approval | Positive | +1.7% | FDA approval for new MACI manufacturing facility in Burlington. |
| Mar 03 | Investor conferences | Neutral | -2.7% | Planned presentations at March 2026 healthcare conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Material positives (BARDA award, FDA facility approval) previously saw gains, while strong earnings and some conference updates coincided with selling, indicating occasional divergence on fundamentally positive news.
Over the last few months, Vericel reported strong Q1 2026 results with revenue of $68.4M and raised 2026 guidance to $326–$336M, yet shares fell 4.49% post-earnings. Earlier, a BARDA contract worth up to $197M and FDA approval of a new MACI manufacturing facility saw positive reactions of 4.85% and 1.66%. Prior conference presentation announcements in March 2026 coincided with a 2.74% decline, providing a reference point for this new Truist MedTech conference notice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. ©2026 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
